Quest Diagnostics (DGX) Cash & Equivalents (2009 - 2026)

Quest Diagnostics has disclosed Cash & Equivalents across 18 years of filings, most recently posting $393.0 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $393.0 million, up 109.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $393.0 million (up 109.04% YoY), and the FY2025 annual result was $420.0 million, down 23.5% from the prior year.
• Cash & Equivalents came in at $393.0 million for Q1 2026 at Quest Diagnostics, down from $420.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $790.0 million in Q2 2022 to a low of $126.0 million in Q2 2023.
• The 5-year median for Cash & Equivalents is $420.0 million (2025), against an average of $438.6 million.
• Across the five-year window, Cash & Equivalents tumbled 84.05% in 2023 and jumped 434.27% in 2024, its largest moves.
• Quest Diagnostics' Cash & Equivalents stood at $315.0 million in 2022, then jumped by 117.78% to $686.0 million in 2023, then declined by 19.97% to $549.0 million in 2024, then retreated by 23.5% to $420.0 million in 2025, then fell by 6.43% to $393.0 million in 2026.
• The last three Cash & Equivalents figures came in at $393.0 million (Q1 2026), $420.0 million (Q4 2025), and $432.0 million (Q3 2025), per Business Quant data.